Company intelligence / Profile preview
Sinovac Biotech Ltd.
Beijing, Beijing, Chinasinovac.com ↗
- Ownership
- Public · SVA
- Employees
- ~4280
- Development stage
- Other
01
Overview
Sinovac has several commercialized vaccines including CoronaVac® for COVID‑19—approved in over 60 countries—plus Healive® for hepatitis A and Inlive® for EV71/Hand-Foot-Mouth Disease. Its COVID‑19 vaccine was validated by WHO Emergency Use Listing in June 2021. The company continues to develop new combination and innovative vaccines with multiple products prequalified by the WHO[4][5][7].
- Therapeutic areas
- Infectious Diseases
- Modalities
- Inactivated vaccineslive attenuated vaccinesrecombinant protein vaccinesmonoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
74 assets73 more assets in the full pipeline.
03
Partnerships
Alagöz Holding Company (Türkiye joint venture)various government procurement partnerships globally
Beyond the preview
Go deeper on Sinovac Biotech Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sinovac Biotech Ltd..